Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis.
TNF inhibitors are being used in a rapidly expanding number of rheumatoid arthritis (RA) patients due to their effectiveness and acceptable safety profiles. To date, concerns regarding the adverse effects of TNF inhibitors have focused on infections, hematologic malignancies, and demyelinating disorders. Recently, the development of autoantibodies and other autoimmunity has been increasingly reported. Here, we describe a 36-year-old RA patient in whom organizing pneumonia and systemic lupus erythematosus were detected during etanercept treatment.
Cho
Soo-Kyung
SK
Department of Rheumatology, Hospital for Rheumatic Diseases, Hanyang University, Seoul 133-792, Korea.
Oh
Il Hwan
IH
Park
Chan Kum
CK
Bae
Sang-Cheol
SC
Sung
Yoon-Kyoung
YK
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D018549:Cryptogenic Organizing Pneumonia / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept